New drug combo tested to fight back when lung cancer stops responding
NCT ID NCT05786430
Summary
This study is testing a three-drug combination (Lazertinib, Pemetrexed, and Carboplatin) for people with a specific type of advanced non-small cell lung cancer. It is for patients whose cancer has started growing again after being treated with the drug Lazertinib alone. The main goal is to see if this new combination can control the cancer and delay its progression for a longer period.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Yonsei University Health System, Severance Hospital
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.